Adoption of Updated WIPO Standard ST.26; Revision to Incorporation by Reference

<RULE> DEPARTMENT OF COMMERCE <SUBAGY>Patent and Trademark Office</SUBAGY> <CFR>37 CFR Part 1</CFR> <DEPDOC>[Docket No. PTO-P-2024-0018]</DEPDOC> <RIN>RIN 0651-AD80</RIN> <SUBJECT>Adoption of Updated WIPO Standard ST.26; Revision to Incorporation by Reference</SUBJECT> <HD SOURCE="HED">AGENCY:</HD> United States Patent and Trademark Office, Department of Commerce. <HD SOURCE="HED">ACTION:</HD> Final rule. <SUM> <HD SOURCE="HED">SUMMARY:</HD> The United States Patent and Trademark Office (USPTO) is adopting version 1.7 of World Intellectual Property Organization (WIPO) Standard ST.26, which was approved December 8, 2023, for incorporation by reference into the USPTO's regulations addressing application disclosures containing nucleotide and/or amino acid sequences. Among other enhancements, version 1.7 of ST.26 provides technical terminology consistency and improves descriptions. The USPTO first amended its rules in 2022 to incorporate by reference certain provisions of WIPO Standard ST.26. In addition to simplifying the process for applicants filing in multiple countries, the ST.26 requirement to submit a single sequence listing in eXtensible Markup Language (XML) format provides better preservation, accessibility, and sorting of the submitted sequence data for the public. </SUM> <EFFDATE> <HD SOURCE="HED">DATES:</HD> This final rule is effective on July 1, 2024. The incorporation by reference of certain publications listed in this rule is approved by the Director of the Federal Register as of July 1, 2024. </EFFDATE> <FURINF> <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD> Ali Salimi, Senior Legal Advisor, at 571-272-0909; or Raul Tamayo, Senior Legal Advisor, at 571-272-7728, both of the Office of Patent Legal Administration; or to <E T="03">PatentPractice@uspto.gov.</E> </FURINF> <SUPLINF> <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD> The “WIPO Handbook on Intellectual Property Information and Documentation” sets forth standards for the presentation of data in many contexts. One such standard is WIPO Standard ST.26, which is titled “RECOMMENDED STANDARD FOR THE PRESENTATION OF NUCLEOTIDE AND AMINO ACID SEQUENCE LISTINGS USING XML (EXTENSIBLE MARKUP LANGUAGE).” WIPO Standard ST.26 defines the disclosures of nucleotide and/or amino acid sequences in patent applications that must be presented in a sequence listing in XML format in the manner specified in the standard. In a final rule published May 20, 2022, at 87 FR 30806, the USPTO created new rules 37 CFR 1.831-1.839 that incorporate by reference WIPO Standard ST.26. 37 CFR 1.839(b)(1) specifically identifies the version of WIPO Standard ST.26 that has been incorporated by reference. In a final rule published May 26, 2023, 88 FR 34089, the USPTO updated 37 CFR 1.839(b)(1) to reflect version 1.6 of WIPO Standard ST.26. On December 8, 2023, WIPO adopted a new version (version 1.7) of WIPO Standard ST.26. As a result, the USPTO is again updating 37 CFR 1.839(b)(1). WIPO provides free online public access to view copies of its standards, including version 1.7 of WIPO Standard ST.26, on its website at <E T="03">www.wipo.int/standards/en/part_03_standards.html.</E> WIPO Standard ST.26 is also available on the USPTO's Sequence Listing Resource Center at <E T="03">www.uspto.gov/patents/apply/sequence-listing-resource-center.</E> WIPO Standard ST.26 is comprised of eight documents: the main body of the standard, a first annex (Annex I) setting forth the controlled vocabulary for use with the main body, Annex II setting forth the Document Type Definition (DTD) for the Sequence Listing, Annex III containing a sequence listing specimen (XML file), Annex IV setting forth the character subset from the Unicode Basic Latin Code Table, Annex V setting forth additional data exchange requirements for IPOs, Annex VI containing a guidance document with illustrated examples, and Annex VII setting forth recommendations for the transformation of a sequence listing from WIPO Standard ST.25 format to WIPO Standard ST.26 format, including guidance on how to avoid adding or deleting subject matter. Revisions to WIPO Standard ST.26 under version 1.7 affect the main body and Annex VI. The changes to the main body improve the consistency of technical terminology. In paragraph 3(f), all instances of “3′-monophosphate” were changed to “5′-monophosphate” to be consistent with paragraph 3(g) and standard nucleotide naming conventions. Similarly, the changes to Annex VI improve consistency and clarity of terminology and correct technical errors. All instances of “3′-monophosphate” were changed to “5′-monophosphate” to be consistent with the changes made to the main body. In Examples 14-1 and 30-2, scientific and grammatical corrections were made to clarify the example disclosures. In addition, Annex VI includes two new examples that demonstrate how sequences with inverted nucleotides should be included in a sequence listing. Finally, the “Example Index” in Annex VI was simplified by removing the “Cross-referenced examples.” Thus, the changes in version 1.7 of WIPO Standard ST.26 are ministerial changes that will not have a meaningful substantive impact on disclosing parties. <HD SOURCE="HD1">Discussion of Specific Rules</HD> <E T="03">Section 1.839:</E> Section 1.839(b)(1) is amended to provide an updated citation to version 1.7 of WIPO Standard ST.26 that is being incorporated by reference. <HD SOURCE="HD1">Rulemaking Considerations</HD> <E T="03">A. Administrative Procedure Act:</E> The changes in this rulemaking involve rules of agency practice and procedure and/or interpretive rules. See <E T="03">Bachow Commc'ns Inc.</E> v. <E T="03">FCC,</E> 237 F.3d 683, 690 (D.C. Cir. 2001) (changes to procedural rules are not subject to notice and comment review under the Administrative Procedure Act (APA)); <E T="03">Inova Alexandria Hosp.</E> v. <E T="03">Shalala,</E> 244 F.3d 342, 349 (4th Cir. 2001) (rules for handling appeals are procedural where they do not change the substantive standard for reviewing claims); <E T="03">Nat'l Org. of Veterans' Advocates</E> v. <E T="03">Sec'y of Veterans Affairs,</E> 260 F.3d 1365, 1375 (Fed. Cir. 2001) (Substantive rules “effect a change in existing law or policy or which affect individual rights and obligations,” whereas interpretative rules “clarify or explain existing law or regulation and are exempt from notice and comment” review under the APA.). Accordingly, prior notice and opportunity for public comment for the changes in this rulemaking are not required pursuant to 5 U.S.C. 553(b) or (c) or any other law. See <E T="03">Cooper Techs. Co.</E> v. <E T="03">Dudas,</E> 536 F.3d 1330, 1336-37 (Fed. Cir. 2008) (stating that 5 U.S.C. 553, and thus 35 U.S.C. 2(b)(2)(B), do not require notice and comment rulemaking for “interpretative rules, general statements of policy, or rules of agency organization, procedure, or practice” (quoting 5 U.S.C. 553(b)(A))). In addition, the USPTO finds good cause pursuant to the authority at 5 U.S.C. 553(b)(B) to dispense with prior notice and opportunity for public comment because such procedures are unnecessary in this instance. The changes in this rulemaking merely update the regulations to incorporate by reference version 1.7 of WIPO Standard ST.26, which was adopted on December 8, 2023, by the WIPO Committee on Standards. These revisions are largely procedural in nature, and do not impose any additional requirements or fees on applicants. Thus, the USPTO implements this final rule without prior notice and opportunity for comment. <E T="03">B. Regulatory Flexibility Act:</E> As prior notice and an opportunity for public comment are not required pursuant to 5 U.S.C. 553 or any other law, neither a Regulatory Flexibility Act analysis nor a certification under the Regulatory Flexibility Act (5 U.S.C. 601 <E T="03">et seq.</E> ) is required. See 5 U.S.C. 603. <E T="03">C. Executive Order 12866 (Regulatory Planning and Review):</E> This rulemaking has been determined to be not significant for purposes of Executive Order 12866 (September 30, 1993), as amended by Executive Order 14094 (April 6, 2023). <E T="03">D. Executive Order 13563 (Improving Regulation and Regulatory Review):</E> The USPTO has complied with Executive Order 13563 (January 18, 2011). Specifically, and as discussed above, the USPTO has, to the extent feasible and applicable: (1) reasonably determined that the benefits of the rule justify its costs; (2) tailored the rule to impose the least burden on society consistent with obtaining the agency's regulatory objectives; (3) selected a regulatory approach that maximizes net benefits; (4) specified performance objectives; (5) identified and assessed available alternatives; (6) involved the public in an open exchange of information and perspectives among experts in relevant disciplines, affected stakeholders in the private sector, and the public as a whole, and provided online access to the rulemaking docket; (7) attempted to promote coordination, simplification, and harmonization across government agencies and identified goals designed to promote innovation; (8) considered approaches that reduce burdens while maintaining flexibility and freedom of choice for the public; and (9) ensured the objectivity of scientific and technological information and processes. <E T="03">E. Executive Order 13132 (Federalism):</E> This rulemaking pertains strictly to federal agency procedures and does not contain policies with federalism implications sufficient to warrant preparation of a Federalism Assessment under Executive Order 13132 (August 4, 1999). <E T="03">F. Executive Order 13175 (Tribal Consultation):</E> This rulemaking will not: (1) have substantial direct effects on one or more Indian tribes; (2) impose substantial direct compliance costs on Indian tribal gover ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ Preview showing 10k of 16k characters. Full document text is stored and available for version comparison. ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━